SaraMichellTolaneyMD

Oncology • Boston, MA

Breast Cancer, Hematologic Oncology

Instructor in Medicine, Dana-Farber Cancer Institute

Join to view full profile

Dr. Tolaney is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Tolaney's full profile

Already have an account?

Office
450 Brookline Ave
Boston, MA 02215
Phone+1 617-632-3800

Fax+1 617-632-1930
Is this information wrong?

Education & Training

Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2005 - 2008
Johns Hopkins UniversityResidency, Internal Medicine, 2002 - 2005
University of California San Francisco School of MedicineClass of 2002

Certifications & Licensure

FL State Medical License 2022 - Present
MA State Medical License 2005 - 2024
American Board of Internal Medicine Medical Oncology

Clinical Trials

Bicalutamide in Treating Patients With Metastatic Breast Cancer Start of enrollment: 2007 Mar 23
Completed
Phase 2
Lapatinib Ditosylate and Akt Inhibitor MK2206 in Treating Women With Metastatic Breast Cancer Start of enrollment: 2011 Jan 01
Terminated
Phase 1
Cabozantinib in Women With Metastatic Hormone-Receptor-Positive Breast Cancer Start of enrollment: 2011 Oct 01
Active, not recruiting
Phase 2
Tivantinib in Treating Patients With Recurrent or Metastatic Breast Cancer Start of enrollment: 2012 Mar 01
Completed
Phase 2
A Safety, Pharmacokinetic and Pharmacodynamic Study of Kevetrin in Patients With Advanced Solid Tumors Start of enrollment: 2012 Oct 01
Completed
Phase 1
Cabozantinib for Metastatic Triple Negative BrCa Start of enrollment: 2013 Feb 01
Completed
Phase 2
T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial) Start of enrollment: 2013 May 01
Active, not recruiting
Phase 2
Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer.(MONALEESA-2) Start of enrollment: 2013 Dec 17
Completed
Phase 3
Study of LEE011 With Fulvestrant and BYL719 or BKM120 in Advanced Breast Cancer Start of enrollment: 2014 May 19
Completed
Phase 1
A Study of Abemaciclib (LY2835219) In Participants With Previously Treated Breast Cancer That Has Spread Start of enrollment: 2014 Jun 10
Completed
Phase 2
A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer Start of enrollment: 2014 Jul 22
Active, not recruiting
Phase 3
Cabozantinib +/- Trastuzumab In Breast Cancer Patients w/ Brain Metastases Start of enrollment: 2014 Nov 01
Completed
Phase 2
An Open-Label, Phase Ib/II Clinical Trial Of Cdk 4/6 Inhibitor, Ribociclib (Lee011), In Combination With Trastuzumab Or T-Dm1 For Advanced/Metastatic Her2-Positive Breast Cancer. Start of enrollment: 2016 Mar 09
Completed
Phase 1, Phase 2
A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer Start of enrollment: 2016 Nov 14
Active, not recruiting
Phase 1
Adjuvant PVX-410 Vaccine and Durvalumab in Stage II/III Triple Negative Breast Cancer Start of enrollment: 2016 Aug 01
Active, not recruiting
Phase 1
Ribociclib (LEE011) Rollover Study for Continued Access Start of enrollment: 2016 Dec 15
Recruiting
Phase 2
A Study Of Changes In PD-L1 Expression During Preoperative Treatment With Nab-Paclitaxel And Pembrolizumab In Hormone Receptor-Positive Breast Cancer Start of enrollment: 2017 Feb 23
Active, not recruiting
Phase 1
CISPLATIN + AZD-1775 In Breast Cancer Start of enrollment: 2017 Jan 18
Completed
Phase 2
A Study Of Pembrolizumab In Combination With Trastuzumab-DM1 Start of enrollment: 2017 Feb 17
Active, not recruiting
Phase 1
A Randomized Phase II Study Of Eribulin Mesylate With or Without Pembrolizumab For Metastatic Hormone Receptor Positive Breast Cancer Start of enrollment: 2017 Mar 22
Completed
Phase 2
Phase II PEMBROLIZUMAB + PALLIATIVE RADIOTHERAPY IN BC Start of enrollment: 2017 May 22
Terminated
Phase 2
A Phase II Study of Nivolumab in Combination With Cabozantinib for Metastatic Triple-negative Breast Cancer Start of enrollment: 2017 Nov 30
Completed
Phase 2
Carboplatin +/- Nivolumab in Metastatic Triple Negative Breast Cancer Start of enrollment: 2018 Jan 30
Active, not recruiting
Phase 2
Olaparib + Sapacitabine in BRCA Mutant Breast Cancer Start of enrollment: 2018 Oct 01
Active, not recruiting
Phase 1
NIMBUS: Nivolumab Plus Ipilimumab in Metastatic Hypermutated HER2-negative Breast Cancer Start of enrollment: 2019 Mar 08
Active, not recruiting
Phase 2
Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC Start of enrollment: 2020 Sep 23
Active, not recruiting
Phase 2
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC Start of enrollment: 2020 Jul 20
Recruiting
Phase 2
ATEMPT 2.0: Adjuvant T-DM1 vs TH Start of enrollment: 2021 Jun 16
Recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

Abnormal vascular structure and function within brain metastases is linked to pembrolizumab resistance.
Ahmed, S., Albert E Kim, Kevin W Lou, Anita Giobbie-Hurder, Ken Chang, Mishka Gidwani, Katharina Hoebel, Jay B Patel, Mason C Cleveland, Praveer Singh, Christopher P B...> ;Neuro-Oncology. 2024 May 3
Impact of dose reductions on adjuvant abemaciclib efficacy for patients with high-risk early breast cancer: analyses from the monarchE study.
Irfan Cicin, Laura Testa, Jens Huober, Valentina Guarneri, Stephen R D Johnston, Miguel Martin, Priya Rastogi, Nadia Harbeck, Ashwin Shahir, Ran Wei, Valérie André, Jo...> ;NPJ Breast Cancer. 2024 Apr 26
Subgroup analyses from the phase 3 ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer.
Sara A Hurvitz, Kevin Punie, Véronique Diéras, Rosemary Delaney, Yanni Zhu, Aditya Bardia, Kevin Kalinsky, Lisa A Carey, Hope S Rugo, See Phan, Sara M Tolaney> ;NPJ Breast Cancer. 2024 Apr 25
Clinicopathological characteristics and eligibility for adjuvant olaparib of germline BRCA1/2 mutation carriers with HER2-negative early breast cancer.
Stefania Morganti, Qingchun Jin, Julie Vincuilla, Ryan Buehler, Sean Ryan, Samantha Stokes, Tonia Parker, Elizabeth A Mittendorf, Tari A King, Anna Weiss, Ann H Partri...> ;NPJ Breast Cancer. 2024 Apr 16
Prognosis and treatment outcomes for patients with stage IA triple-negative breast cancer.
Julieta Leone, Carlos T Vallejo, Olga Martínez-Sáez, Nabihah Tayob, Paolo Tarantino, Rachel A Freedman, Adrienne G Waks, Ana Garrido-Castro, Filipa Lynce, Nancy U Lin,...> ;NPJ Breast Cancer. 2024 Apr 4
Clinical outcomes after 1 versus 2-3 lines of neoadjuvant therapy in stage III inflammatory breast cancer.
Faina Nakhlis, Samuel M Niman, Naoto T Ueno, Elizabeth Troll, Sean Ryan, Eren Yeh, Laura Warren, Jennifer Bellon, Beth Harrison, Toshiaki Iwase, H T Carisa Le-Petross,...> ;Breast Cancer Research and Treatment. 2024 Apr 1
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study.
Filipa Lynce, Candace Mainor, Renee N Donahue, Xue Geng, Greg Jones, Ilana Schlam, Hongkun Wang, Nicole J Toney, Caroline Jochems, Jeffrey Schlom, Jay Zeck, Christophe...> ;Nature Communications. 2024 Mar 27
PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Horm...
Erica L Mayer, Yue Ren, Nikhil Wagle, Reshma Mahtani, Cynthia Ma, Angela DeMichele, Massimo Cristofanilli, Jane Meisel, Kathy D Miller, Yara Abdou, Elizabeth C Riley, ...> ;Journal of Clinical Oncology. 2024 Mar 21
Exemestane plus everolimus and palbociclib in metastatic breast cancer: clinical response and genomic/transcriptomic determinants of resistance in a phase I/II trial.
Jorge Gómez Tejeda Zañudo, Romualdo Barroso-Sousa, Esha Jain, Qingchun Jin, Tianyu Li, Jorge E Buendia-Buendia, Alyssa Pereslete, Daniel L Abravanel, Arlindo R Ferreir...> ;Nature Communications. 2024 Mar 19
Author Correction: Liquid biopsy epigenomic profiling for cancer subtyping.
Ligon, K. L., Sylvan C Baca, Ji-Heui Seo, Matthew P Davidsohn, Brad Fortunato, Karl Semaan, Shahabbedin Sotudian, Gitanjali Lakshminarayanan, Miklos Diossy, Xintao Qiu...> ;Nature Medicine. 2024 Mar 1
Mortality Risks Over 20 Years in Men With Stage I to III Hormone Receptor-Positive Breast Cancer.
Julieta Leone, Michael J Hassett, Rachel A Freedman, Sara M Tolaney, Noah Graham, Nabihah Tayob, Carlos T Vallejo, Eric P Winer, Nancy U Lin, José P Leone> ;JAMA Oncology. 2024 Apr 1
Final Results From the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Fac...
Aditya Bardia, Hope S Rugo, Sara M Tolaney, Delphine Loirat, Kevin Punie, Mafalda Oliveira, Adam Brufsky, Kevin Kalinsky, Javier Cortés, Joyce O' Shaughnessy, Véroniqu...> ;Journal of Clinical Oncology. 2024 Feb 29
Evolution of HER2 expression between pre-treatment biopsy and residual disease after neoadjuvant therapy for breast cancer.
Ajari, O., Graham, N., Vincuilla, J., Parker, T., Hughes, M., Tayob, N., Morganti, S., Curigliano, G., Tarantino, P., Garrido-Castro, A., King, T., Mittendorf, E., Lin...> ;European Journal of Cancer. 2024 Apr 1
Estrogen Receptor Mutations as Novel Targets for Immunotherapy in Metastatic Estrogen Receptor-positive Breast Cancer.
Qiao, N., Guerriero, J., Gross, B., Meneksedag, Y., Lu, Y., Philips, A., Roszik, J., Chen, K., Peoples, G., Alatrash, G., Goldberg, J., Rahman, T., Meric-Bernstam, F.,...> ;Cancer Research Communications. 2024 Feb 22
TBCRC 039: a phase II study of preoperative ruxolitinib with or without paclitaxel for triple-negative inflammatory breast cancer.
Filipa Lynce, Laura E Stevens, Zheqi Li, Jane E Brock, Anushree Gulvady, Ying Huang, Faina Nakhlis, Ashka Patel, Jeremy M Force, Tufia C Haddad, Naoto Ueno, Vered Stea...> ;Breast Cancer Research. 2024 Jan 31
Impact of personalized diabetes care on distress and treatment satisfaction in people with breast cancer.
Harrod, J., Buckley, L., Cromwell, G., Fowler, K., Hughes, M., Cheung, Y., Lin, N., Tolaney, S., Min, L., McDonnell, M.> ;Diabetic Medicine. 2024 Apr 1
A plain language summary of the TROPiCS-02 study in patients with breast cancer (HR-positive/HER2-negative).
Hope S Rugo, Aditya Bardia, Frederik Marmé, Javier Cortés, Peter Schmid, Patricia A Spears, Sara M Tolaney> ;Future Oncology. 2024 Apr 1
ASO Visual Abstract: Defining the Biology of Estrogen Receptor-Low Positive Breast Cancer.
Higgins, T., Harrison, B., Giordano, J., McGrath, M., Kantor, O., Burstein, H., Schnitt, S., Rahman, T., Vora, H., Garrido-Castro, A., Tolaney, S., Meric-Bernstam, F.,...> ;Annals of Surgical Oncology. 2024 Apr 1
Long-term patient-reported outcomes from monarchE: Abemaciclib plus endocrine therapy as adjuvant therapy for HR+, HER2-, node-positive, high-risk, early breast cancer.
Guarneri, V., Seo, J., Cruz, J., Abreu, M., Takahashi, M., Barrios, C., McIntyre, K., Wei, R., Munoz, M., Antonio, B., Liepa, A., Martin, M., Johnston, S., Kellokumpu-...> ;European Journal of Cancer. 2024 Mar 1
Prevalence, Dynamics, and Prognostic Role of Clonal Hematopoiesis of Indeterminate Potential in Patients With Breast Cancer.
Stefania Morganti, Christopher J Gibson, Qingchun Jin, Katheryn Santos, Ashka Patel, Alex Wilson, Margaret Merrill, Julie Vincuilla, Samantha Stokes, Marla Lipsyc-Shar...> ;Journal of Clinical Oncology. 2024 Jan 8
Immunotherapy for Early-Stage Triple Negative Breast Cancer: Is Earlier Better?
Song, F., Tarantino, P., Garrido-Castro, A., Lynce, F., Tolaney, S., Schlam, I.> ;Current Oncology Reports. 2024 Jan 1
Qualification of a multiplexed tissue imaging assay and detection of novel patterns of HER2 heterogeneity in breast cancer.
Guerriero, J., Lin, J., Pastorello, R., Du, Z., Chen, Y., Townsend, M., Shimada, K., Hughes, M., Ren, S., Tayob, N., Zheng, K., Mei, S., Patterson, A., Taneja, K., Met...> ;NPJ Breast Cancer. 2024 Jan 2
1 citations
Defining the Biology of Estrogen Receptor-Low-Positive Breast Cancer.
Higgins, T., Harrison, B., Giordano, J., McGrath, M., Kantor, O., Burstein, H., Schnitt, S., Rahman, T., Vora, H., Garrido-Castro, A., Tolaney, S., Meric-Bernstam, F.,...> ;Annals of Surgical Oncology. 2024 Apr 1
Advancing equitable and personalized cancer care: Novel applications and priorities of artificial intelligence for fairness and inclusivity in the patient care workflow.
Cobanaj, M., Corti, C., McCullum, L., Boldrini, L., Celi, L., Curigliano, G., Criscitiello, C., Dee, E., Schlam, I., Tolaney, S.> ;European Journal of Cancer. 2024 Feb 1
HER2/ERBB2 copy number analysis by targeted next-generation sequencing in breast cancer.
Daniel Xia, Frank Kuo, Melissa Hughes, Neal Lindeman, Danielle Manning, Janet Files, Sarah Strauss, Greg Kirkner, Ayesha Mohammed-Abreu, Eric Winer, Sara M Tolaney, Na...> ;American Journal of Clinical Pathology. 2024 May 2
Join now to see all

Journal Articles

Effect of Eribulin with or Without Pembrolizumab on Progression-Free Survival for Patients with Hormone Receptor–Positive, ERBB2-Negative Metastatic Breast Cancer
Sara M Tolaney, Gerburg Wulf, Laura Spring, Beth Overmoyer, Ann H Partridge, Eric P Winer, Ian E Krop, JAMA Oncology

Lectures

Randomized phase II study of eribulin mesylate (E) with or without pembrolizumab (P) for hormone receptor-positive (HR+) metastatic breast cancer (MBC).
2019 ASCO Annual Meeting - 6/1/2019
New Frontiers in HER2-Positive Breast Cancer
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
Impact of abemaciclib on the time to subsequent chemotherapy and the time to second disease progression across the MONARCH 2 and 3 studies.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
Updated efficacy, safety, & PD-L1 status of patients with HR+, HER2- metastatic breast cancer administered abemaciclib plus pembrolizumab.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
Join now to see all

Press Mentions

Phase 3 Studies for Rectal, Brain, and Kidney Cancers to Be Presented by Dana-Farber Researchers at ASCO 2023May 26th, 2023
Leaders in Breast and Lung Cancer Treatment Join SystImmune Inc's Clinical Science Advisory CommitteeApril 26th, 2023
Dana-Farber Research Supports FDA Approval of New Therapy for Metastatic Breast CancerFebruary 3rd, 2023
Join now to see all